Selected phase 3 trials for FDA-approved frontline regimens for fit patients
| Trial . | Duration . | ORR, % . | PFS . |
|---|---|---|---|
| CLL8: FCR29 | Up to 6 cycles | 90 | 56.8 mo (est. 36-mo PFS, 65%) |
| CLL10: FCR30 | Up to 6 cycles | 95 | 55.2 mo (est. 36-mo PFS, 70%) |
| CLL10: BR30 | Up to 6 cycles | 96 | 41.7 mo (est. 36 mo PFS, 58%) |
| E1912*: IR37 | Continuous ibrutinib, rituximab 6 cycles | 96 | Est. 36-mo PFS, 89% |
| E1912*: FCR37 | Up to 6 cycles | 81 | Est. 36-mo PFS, 73% |
| Trial . | Duration . | ORR, % . | PFS . |
|---|---|---|---|
| CLL8: FCR29 | Up to 6 cycles | 90 | 56.8 mo (est. 36-mo PFS, 65%) |
| CLL10: FCR30 | Up to 6 cycles | 95 | 55.2 mo (est. 36-mo PFS, 70%) |
| CLL10: BR30 | Up to 6 cycles | 96 | 41.7 mo (est. 36 mo PFS, 58%) |
| E1912*: IR37 | Continuous ibrutinib, rituximab 6 cycles | 96 | Est. 36-mo PFS, 89% |
| E1912*: FCR37 | Up to 6 cycles | 81 | Est. 36-mo PFS, 73% |
est./Est., estimated.
Did not enroll patients with del17p.